Study Summary
This is a single-arm, open-label phase I study to determine the safety, tolerability, and recommended dose (RD) of CAR-T-19 cells for patients with CD19+ relapse/refractory B-ALL under the age of 25.
Want to learn more about this trial?
Request More InfoInterventions
CAR-T-19 CellsBIOLOGICAL
T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Chinese PLA General Hospital | Beijing | Beijing Municipality | China |